143 related articles for article (PubMed ID: 19251094)
1. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
Feng M; Kong FM; Gross M; Fernando S; Hayman JA; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1228-34. PubMed ID: 19251094
[TBL] [Abstract][Full Text] [Related]
2. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.
Markovina S; Duan F; Snyder BS; Siegel BA; Machtay M; Bradley JD
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):597-605. PubMed ID: 26461002
[TBL] [Abstract][Full Text] [Related]
3. Personalized mid-course FDG-PET based adaptive treatment planning for non-small cell lung cancer using machine learning and optimization.
Ajdari A; Liao Z; Mohan R; Wei X; Bortfeld T
Phys Med Biol; 2022 Sep; 67(18):. PubMed ID: 35947984
[No Abstract] [Full Text] [Related]
4. A Prospective Study Comparing Dosimetry between Computed Tomography (CT) based Radiation Planning and Positron Emission Computed Tomography (PET-CT) based Radiation Planning in Treatment of Non-Metastatic Non Small Cell Lung Carcinoma.
Mandal B; Basu A; Manna A; Mondal J; Ghosh D; Chakraborty I; Biswas J; Chakraborty A
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2543-2550. PubMed ID: 37505789
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of radiation therapy-induced vasculitis using [
Evanson D; Griffin M; O'Reilly SE; Johnson T; Werner T; Kothekar E; Jahangiri P; Simone CB; Swisher-McClure S; Feigenberg SJ; Revheim ME; Zou J; Alavi A
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1444-1450. PubMed ID: 38095673
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial: Should dose intensification be discontinued or should accelerated schemes remain an important area of clinical research?
Arcidiacono F; Anselmo P; Casale M; Trippa F
Radiother Oncol; 2023 Aug; 185():109688. PubMed ID: 37164107
[No Abstract] [Full Text] [Related]
7. FDG-PET/CT imaging for tumor staging and definition of tumor volumes in radiation treatment planning in non-small cell lung cancer.
Zheng Y; Sun X; Wang J; Zhang L; DI X; Xu Y
Oncol Lett; 2014 Apr; 7(4):1015-1020. PubMed ID: 24944661
[No Abstract] [Full Text] [Related]
8. Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?
Kernstine KH; Faubert B; Do QN; Rogers TJ; Hensley CT; Cai L; Torrealba J; Oliver D; Wachsmann JW; Lenkinski RE; Malloy CR; Deberardinis RJ
Ann Thorac Surg; 2020 Apr; 109(4):1019-1025. PubMed ID: 31846640
[TBL] [Abstract][Full Text] [Related]
9. Dose-Response Relationship Between Radiation Therapy and Loss of Lung Perfusion Comparing Positron Emission Tomography and Dual-Energy Computed Tomography in Non-Small Cell Lung Cancer.
Gaudreault M; Bucknell N; Woon B; Kron T; Hofman MS; Siva S; Hardcastle N
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):1135-1143. PubMed ID: 37914141
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of Isotoxic Dose-escalated Radiotherapy in Lung Cancer with Moderate Deep Inspiration Breath Hold, Mid-ventilation and Internal Target Volume Techniques.
Bainbridge H; Dunlop A; McQuaid D; Gulliford S; Gunapala R; Ahmed M; Locke I; Nill S; Oelfke U; McDonald F
Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):151-159. PubMed ID: 34503896
[TBL] [Abstract][Full Text] [Related]
11. Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?
Gates EDH; Hippe DS; Vesselle HJ; Zeng J; Bowen SR
Radiother Oncol; 2023 Aug; 185():109720. PubMed ID: 37244360
[TBL] [Abstract][Full Text] [Related]
12. BIOGUIDE-X: A First-in-Human Study of the Performance of Positron Emission Tomography-Guided Radiation Therapy.
Vitzthum LK; Surucu M; Gensheimer MF; Kovalchuk N; Han B; Pham D; Chang D; Shirvani SM; Aksoy D; Maniyedath A; Narayanan M; Da Silva AJ; Mazin S; Feghali KAA; Iyengar P; Dan T; Pompos A; Timmerman R; Öz O; Cai B; Garant A
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1172-1180. PubMed ID: 38147912
[TBL] [Abstract][Full Text] [Related]
13. Differential Response of Pelvic Bone Marrow Fluorodeoxyglucose Uptake in Patients Receiving Concurrent Chemoradiotherapy.
Robinson M; Muirhead R; McGowan DR; Chu KY; Jacobs C; Hawkins MA
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):e622-e627. PubMed ID: 37339923
[TBL] [Abstract][Full Text] [Related]
14. Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks.
Jemaa S; Fredrickson J; Carano RAD; Nielsen T; de Crespigny A; Bengtsson T
J Digit Imaging; 2020 Aug; 33(4):888-894. PubMed ID: 32378059
[No Abstract] [Full Text] [Related]
15. The use of positron emission tomography imaging to guide radiation therapy.
Koontz BF; Kasibhatla MS
Clin Adv Hematol Oncol; 2023 Oct; 21(10):549-557. PubMed ID: 37948591
[TBL] [Abstract][Full Text] [Related]
16. Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer.
Salem A; Little RA; Latif A; Featherstone AK; Babur M; Peset I; Cheung S; Watson Y; Tessyman V; Mistry H; Ashton G; Behan C; Matthews JC; Asselin MC; Bristow RG; Jackson A; Parker GJM; Faivre-Finn C; Williams KJ; O'Connor JPB
Clin Cancer Res; 2019 Jul; 25(13):3818-3829. PubMed ID: 31053599
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model.
Liu X; Jiang C; Zhang D; Gao M; Peng F; Huang D; Sun Z; Ni Y; Zhang J; Yin Z
Oncotarget; 2015 Sep; 6(28):26400-10. PubMed ID: 26305548
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Function Modifies the Impact of Heart Base Dose on Survival: A Voxel-Wise Analysis of Patients With Lung Cancer From the PET-Plan Trial.
Craddock M; Nestle U; Koenig J; Schimek-Jasch T; Kremp S; Lenz S; Banfill K; Davey A; Price G; Salem A; Faivre-Finn C; van Herk M; McWilliam A
J Thorac Oncol; 2023 Jan; 18(1):57-66. PubMed ID: 36130693
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA; Belderbos JSA; Reymen B; Lambrecht M; Fredberg Persson G; Faivre-Finn C; Dieleman EMT; van Diessen JNA; Sonke JJ; de Ruysscher D
Radiother Oncol; 2024 Apr; 196():110312. PubMed ID: 38663582
[TBL] [Abstract][Full Text] [Related]
20. Imaging primary lung cancers in mice to study radiation biology.
Kirsch DG; Grimm J; Guimaraes AR; Wojtkiewicz GR; Perez BA; Santiago PM; Anthony NK; Forbes T; Doppke K; Weissleder R; Jacks T
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):973-7. PubMed ID: 20206017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
